Skip to main content

Market Overview

Agentix Biopharma CEO, Rudy Mazzocchi, Discusses the Company's Growth Strategy with The Stock Day Podcast

Share:

Phoenix, Arizona--(Newsfile Corp. - November 11, 2020) - The Stock Day Podcast welcomed Agentix Biopharma (OTC:AGTX) ("the Company"), a biotechnology company focused on the development of synthetic agonists, inverse agonists and antagonists which modulate the endocannabinoid system (ECS). CEO of the Company, Rudy Mazzocchi, joined Stock Day host Everett Jolly.

Jolly began the interview by asking about the Company's background and current projects. Mazzocchi shared that the Company is a biopharmaceutical company focused in the cannabinoid space. "We have three programs, each with ongoing separate developments of specific assets," said Mazzocchi. "We have an over-the-counter (OTC) health and wellness product line with a strong differentiating technology known as a cannabinoid-biocomplex," shared Mazzocchi. "Secondly, we have a cannabinoid-based series of established pharmaceutical products for oncology, dermatology, and neurology," he continued. "Our third program focuses on proprietary molecules that we refer to as Innovative Pharmaceuticals that interact with the peripheral endocannabinoid receptors (CB1 & CB2)."

"How did this team come together?" asked Jolly. "I've been a serial start-up CEO since the late 80s in the med-tech and biotech industry," shared Mazzocchi. "In my career, I've been asked by several private equity and venture firms to step in to drive a process to get a company prepared for IPO, so this is right in my wheelhouse," said Mazzocchi. "I'm very fortunate to have a strong scientific team with me," he added before elaborating on the members of the Company's team. "We've also engaged a great Scientific Advisory Board that we are actually expanding as we speak."

Jolly then asked about the potential of up-listing to the OTCQB or NASDAQ in the future. "Our goal is to up-list to the NASDAQ; we filed an S1 registration statement that became effective several weeks ago," explained Mazzocchi, "and in the process of filing for the certification with the OTCQB. Right now, we're focused on expanding our investor awareness and preparing ourselves for a potential financing that will help bridge the up-listing to NASDAQ."

"Has the election had any effect on this?" asked Jolly. "I think having President-elect Biden in place is going to help increase the validity of this market segment and improve the regulatory conditions as we up-list to the NASDAQ," said Mazzocchi.

"What differentiates your company from the other cannabinoids that are in this space?" asked Jolly. Mazzocchi discussed the Company's partnership with a private New York based company, which has allowed them to co-develop a proprietary delivery system for the controlled release of micro-doses of cannabinoids through a novel 'cannabinoid-biocomplex' which provides for controlled delivery at the cellular level. "This key element differentiates us," said Mazzocchi. "We intend to carry this type of development into our other proprietary pharmaceutical applications as well."

To close the interview, Mazzocchi shared that the Company is dedicated to providing high-quality, strongly validated pharmaceuticals to the growing cannabinoid industry.

To hear Rudy Mazzocchi's entire interview, follow the link to the podcast here: https://audioboom.com/posts/7727557-agentix-biopharma-ceo-rudy-mazzocchi-discusses-the-company-s-growth-strategy-with-the-stock-day

Investors Hangout is a proud sponsor of "Stock Day," and Stock Day Media encourages listeners to visit the company's message board at https://investorshangout.com/

About Agentix Biopharma

Agentix Biopharma is a biotechnology company focused on the development of synthetic agonists, inverse agonists and antagonists which modulate the endocannabinoid system (ECS). The ECS is a network of G-protein coupled receptors (GPCRs) that help regulate a variety of metabolic and neurotransmission functions. GPCRs are considered the largest family of proven therapeutic targets. To date there are over 134 drugs approved in the United States or the European Union which target GPCRs generating several billion dollars annually in revenues for pharmaceutical companies.

Agentix Biopharma has developed partnerships with leading academic and research institutions. Agentix Biopharma has exclusively licensed patented, synthetically-derived, small molecule therapeutic candidates targeting the endocannabinoid GPCRs (CB1/CB2) for the treatment of metabolic syndrome and peripheral inflammation. Agentix Biopharma is advancing these therapeutic product candidates in clinical trials.

Investor Relations

ir@agentixcorp.com

Company Contact

Agentix Corp.

32932 Pacific Coast Highway

Dana Point, CA 92629

About The "Stock Day" Podcast

Founded in 2013, Stock Day is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Stock Day provides companies with customized solutions to their news distribution in both national and international media outlets. The Stock Day Podcast is the number one radio show of its kind in America. Stock Day recently launched its Video Interview Studio located in Phoenix, Arizona.

SOURCE:

Stock Day Media
(602) 821-1102

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/67968

View Comments and Join the Discussion!
 
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com